Myocardial Metabolism in Diabetic Cardiomyopathy: Potential Therapeutic Targets

Antioxidants and Redox Signaling

Volumn 22, Issue 17, 2015, Pages 1606-1630

  Sung, Miranda M ^a   Hamza, Shereen M ^a   Dyck, Jason R B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ETOMOXIR; FATTY ACID; GLUCOSE; INSULIN; PERHEXILINE; RANOLAZINE; RESVERATROL; TRIACYLGLYCEROL; TRIMETAZIDINE; ANTIOXIDANT; STILBENE DERIVATIVE;

BIOGENESIS; CALCIUM TRANSPORT; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC CARDIOMYOPATHY; DRUG TARGETING; ENERGY METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HUMAN; LIFESTYLE MODIFICATION; LIPID STORAGE; LIPOLYSIS; LIPOTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; METABOLISM; MITOCHONDRION;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; HUMANS; MITOCHONDRIA; MYOCARDIUM; STILBENES;

EID: 84930652768     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6305     Document Type: Review

References (297)

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 854-865, 1998.
2. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, and Larsen TS. Cardiac function and metabolism in type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol 283: H949-H957, 2002.
3. Aliciguzel Y, Ozen I, Aslan M, and Karayalcin U. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 142: 172-177, 2003.
4. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, and Neufer PD. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 54: 1891-1898, 2009.
5. Aon MA, Cortassa S, and O'Rourke B. Redox-optimized ROS balance: a unifying hypothesis. Biochim Biophys Acta 1797: 865-877, 2010.
6. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, and Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 273: 5678-5684, 1998.
7. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, Rybkin II, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, and Spiegelman BM. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 1: 259-271, 2005.
8. Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic Res Cardiol 104: 181-188, 2009.
9. Bajraktari G, Koltai MS, Ademaj F, Rexhepaj N, Qirko S, Ndrepepa G, and Elezi S. Relationship between insulin resistance and left ventricular diastolic dysfunction in patients with impaired glucose tolerance and type 2 diabetes. Int J Cardiol 110: 206-211, 2006.
10. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, and Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342, 2006.
11. Bayeva M, Sawicki KT, and Ardehali H. Taking diabetes to heart - deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc 2: e000433, 2013.
12. Beaudoin MS, Perry CG, Arkell AM, Chabowski A, Simpson JA, Wright DC, and Holloway GP. Impairments in mitochondrial palmitoyl-CoA respiratory kinetics that precede development of diabetic cardiomyopathy are prevented by resveratrol in ZDF rats. J Physiol 592: 2519-2533, 2014.
13. Belke DD, Betuing S, Tuttle MJ, Graveleau C, Young ME, Pham M, Zhang D, Cooksey RC, McClain DA, Litwin SE, Taegtmeyer H, Severson D, Kahn CR, and Abel ED. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J Clin Invest 109: 629-639, 2002.
14. Belke DD, Larsen TS, Gibbs EM, and Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279: E1104-E1113, 2000.
15. Belke DD, Swanson EA, and Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53: 3201-3208, 2004.
16. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18: 708-714, 1995.
17. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, Coleman T, Mecham RP, Kelly DP, and Semenkovich CF. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 9: 1069-1075, 2003.
18. Bhamra GS, Hausenloy DJ, Davidson SM, Carr RD, Paiva M, Wynne AM, Mocanu MM, and Yellon DM. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 103: 274-284, 2008.
19. Bhatt JK, Thomas S, and Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32: 537-541, 2012.
20. Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, and Besch HR, Jr. Diabetes increases formation of advanced glycation end products on sarco(endo) plasmic reticulum Ca2+-ATPase. Diabetes 53: 463-473, 2004.
21. Bloomgarden ZT. Diabetes complications. Diabetes Care 27: 1506-1514, 2004.
22. Boardman NT, Aronsen JM, Louch WE, Sjaastad I, Willoch F, Christensen G, Sejersted O, and Aasum E. Impaired left ventricular mechanical and energetic function in mice after cardiomyocyte-specific excision of Serca2. Am J Physiol Heart Circ Physiol 306: H1018-H1024, 2014.
23. Boudina S and Abel ED. Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology (Bethesda) 21: 250-258, 2006.
24. Boudina S, Bugger H, Sena S, O'Neill BT, Zaha VG, Ilkun O, Wright JJ, Mazumder PK, Palfreyman E, Tidwell TJ, Theobald H, Khalimonchuk O, Wayment B, Sheng X, Rodnick KJ, Centini R, Chen D, Litwin SE, Weimer BE, and Abel ED. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119: 1272-1283, 2009.
25. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, and Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112: 2686-2695, 2005.
26. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, and Abel ED. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56: 2457-2466, 2007.
27. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, and Parker N. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 37: 755-767, 2004.
28. Brand MD and Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab 2: 85-93, 2005.
29. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J, Mikolas E, Szijarto IA, Merei A, Halmai R, Meszaros LG, Sumegi B, and Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106: 383-389, 2011.
30. Bresciani L, Calani L, Bocchi L, Delucchi F, Savi M, Ray S, Brighenti F, Stilli D, and Del Rio D. Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr Metab Cardiovasc Dis 24: 408-415, 2014.
31. Brindley DN, Kok BP, Kienesberger PC, Lehner R, and Dyck JR. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab 298: E897-E908, 2010.
32. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, and Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146: 5341-5349, 2005.
33. Bugger H and Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2: 454-466, 2009.
34. Bugger H and Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res 88: 229-240, 2010.
35. Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, Yun UJ, McQueen AP, Wayment B, Litwin SE, and Abel ED. Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3. Diabetes 57: 2924-2932, 2008.
36. Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, Weimer BC, and Abel ED. Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes 58: 1986-1997, 2009.
37. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, and Lopaschuk GD. A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277: 4098-4103, 2002.
38. Candido R, Srivastava P, Cooper ME, and Burrell LM. Diabetes mellitus: a cardiovascular disease. Curr Opin Investig Drugs 4: 1088-1094, 2003.
39. Carley AN, Atkinson LL, Bonen A, Harper ME, Kunnathu S, Lopaschuk GD, and Severson DL. Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch Physiol Biochem 113: 65-75, 2007.
40. Carolo Dos Santos K, Pereira Braga C, Octavio Barbanera P, Rodrigues Ferreira Seiva F, Fernandes Junior A, and Fernandes AA. Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol. PLoS One 9: e102775, 2014.
41. Chatham JC and Seymour AM. Cardiac carbohydrate metabolism in Zucker diabetic fatty rats. Cardiovasc Res 55: 104-112, 2002.
42. Chen YR and Zweier JL. Cardiac mitochondria and reactive oxygen species generation. Circ Res 114: 524-537, 2014.
43. Cheng AY and Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172: 213-226, 2005.
44. Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S, Thorn V, Harmon C, Barr R, Dyck JR, Lopaschuk GD, and Nadzan AM. Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors. J Med Chem 49: 1517-1525, 2006.
45. Cheng JF, Huang Y, Penuliar R, Nishimoto M, Liu L, Arrhenius T, Yang G, O'Leary E, Barbosa M, Barr R, Dyck JR, Lopaschuk GD, and Nadzan AM. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents. J Med Chem 49: 4055-4058, 2006.
46. Cheng JF, Mak CC, Huang Y, Penuliar R, Nishimoto M, Zhang L, Chen M, Wallace D, Arrhenius T, Chu D, Yang G, Barbosa M, Barr R, Dyck JR, Lopaschuk GD, and Nadzan AM. Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors. Bioorg Med Chem Lett 16: 3484-3488, 2006.
47. Chi TC, Chen WP, Chi TL, Kuo TF, Lee SS, Cheng JT, and Su MJ. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci 80: 1713-1720, 2007.
48. Chisholm JW, Goldfine AB, Dhalla AK, Braunwald E, Morrow DA, Karwatowska-Prokopczuk E, and Belardinelli L. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 33: 1163-1168, 2010.
49. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, and Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96: 225-233, 2005.
50. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, and Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813-822, 2001.
51. Choksi KB, Boylston WH, Rabek JP, Widger WR, and Papaconstantinou J. Oxidatively damaged proteins of heart mitochondrial electron transport complexes. Biochim Biophys Acta 1688: 95-101, 2004.
52. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA, Walser M, Sama M, Aimaretti G, Isgaard J, and Sacca L. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 61: 944-953, 2012.
53. Cohen-Solal A, Beauvais F, and Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 14: 615-625, 2008.
54. Cook SA, Varela-Carver A, Mongillo M, Kleinert C, Khan MT, Leccisotti L, Strickland N, Matsui T, Das S, Rosenzweig A, Punjabi P, and Camici PG. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J 31: 100-111, 2010.
55. Coort SL, Hasselbaink DM, Koonen DP, Willems J, Coumans WA, Chabowski A, van der Vusse GJ, Bonen A, Glatz JF, and Luiken JJ. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 53: 1655-1663, 2004.
56. Coort SL, Willems J, Coumans WA, van der Vusse GJ, Bonen A, Glatz JF, and Luiken JJ. Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem 239: 213-219, 2002.
57. Cortassa S, O'Rourke B, and Aon MA. Redox-optimized ROS balance and the relationship between mitochondrial respiration and ROS. Biochim Biophys Acta 1837: 287-295, 2014.
58. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, and Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54: 7-16, 2010.
59. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, and Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 67: 1307-1312, 2012.
60. Cuthbert KD and Dyck JR. Malonyl-CoA decarboxylase is a major regulator of myocardial fatty acid oxidation. Curr Hypertens Rep 7: 407-411, 2005.
61. Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, and Chen HH. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail 20: 304-309, 2014.
62. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, and Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101: 2271-2276, 2000.
63. Dhalla NS, Rangi S, Zieroth S, and Xu YJ. Alterations in sarcoplasmic reticulum and mitochondrial functions in diabetic cardiomyopathy. Exp Clin Cardiol 17: 115-120, 2012.
64. Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, Turco S, Capaldo B, and Sibilio G. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabet Med 22: 1720-1725, 2005.
65. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, and Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42: 328-335, 2003.
66. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, and Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29: 2388-2442, 2008.
67. Dimitropoulos G, Tahrani AA, and Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes 5: 17-39, 2014.
68. Dolinsky VW, Jones KE, Sidhu RS, Haykowsky M, Czubryt MP, Gordon T, and Dyck JR. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J Physiol 590: 2783-2799, 2012.
69. Dong F, Zhang X, Yang X, Esberg LB, Yang H, Zhang Z, Culver B, and Ren J. Impaired cardiac contractile function in ventricular myocytes from leptin-deficient ob/ob obese mice. J Endocrinol 188: 25-36, 2006.
70. Drose S, Brandt U, and Wittig I. Mitochondrial respiratory chain complexes as sources and targets of thiol-based redox-regulation. Biochim Biophys Acta 1844: 1344-1354, 2014.
71. Duchen MR. Roles of mitochondria in health and disease. Diabetes 53 Suppl 1: S96-S102, 2004.
72. Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 1813: 1351-1359, 2011.
73. Duncan JG and Finck BN. The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium. PPAR Res 2008: 253817, 2008.
74. Duncan JG, Fong JL, Medeiros DM, Finck BN, and Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 115: 909-917, 2007.
75. Durgan DJ, Smith JK, Hotze MA, Egbejimi O, Cuthbert KD, Zaha VG, Dyck JR, Abel ED, and Young ME. Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol 290: H2480-H2497, 2006.
76. Dutta K, Podolin DA, Davidson MB, and Davidoff AJ. Cardiomyocyte dysfunction in sucrose-fed rats is associated with insulin resistance. Diabetes 50: 1186-1192, 2001.
77. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, and Lopaschuk GD. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94: e78-e84, 2004.
78. Dyntar D, Eppenberger-Eberhardt M, Maedler K, Pruschy M, Eppenberger HM, Spinas GA, and Donath MY. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 50: 2105-2113, 2001.
79. Evans JL, Goldfine ID, Maddux BA, and Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1-8, 2003.
80. Faria AM, Papadimitriou A, Silva KC, Lopes de Faria JM, and Lopes de Faria JB. Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in experimental diabetes by re-establishing tetrahydrobiopterin levels. Diabetes 61: 1838-1847, 2012.
81. Fauconnier J, Lanner JT, Zhang SJ, Tavi P, Bruton JD, Katz A, and Westerblad H. Insulin and inositol 1,4,5-trisphosphate trigger abnormal cytosolic Ca2+ transients and reveal mitochondrial Ca2+ handling defects in cardiomyocytes of ob/ob mice. Diabetes 54: 2375-2381, 2005.
82. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DP. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A 100: 1226-1231, 2003.
83. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, and Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121-130, 2002.
84. Flarsheim CE, Grupp IL, and Matlib MA. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol 271: H192-H202, 1996.
85. From AM, Leibson CL, Bursi F, Redfield MM, Weston SA, Jacobsen SJ, Rodeheffer RJ, and Roger VL. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 119: 591-599, 2006.
86. Fu Q, Xu B, Liu Y, Parikh D, Li J, Li Y, Zhang Y, Riehle C, Zhu Y, Rawlings T, Shi Q, Clark RB, Chen X, Abel ED, and Xiang YK. Insulin inhibits cardiac contractility by inducing a Gi-biased beta2-adrenergic signaling in hearts. Diabetes 63: 2676-2689, 2014.
87. Fulop N, Mason MM, Dutta K, Wang P, Davidoff AJ, Marchase RB, and Chatham JC. Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am J Physiol Cell Physiol 292: C1370-C1378, 2007.
88. Galderisi M, Anderson KM, Wilson PW, and Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68: 85-89, 1991.
89. Garciarena CD, Caldiz CI, Correa MV, Schinella GR, Mosca SM, Chiappe de Cingolani GE, Cingolani HE, and Ennis IL. Na+/H+ exchanger-1 inhibitors decrease myocardial superoxide production via direct mitochondrial action. J Appl Physiol (1985) 105: 1706-1713, 2008.
90. Ge F, Hu C, Hyodo E, Arai K, Zhou S, Lobdell Ht, Walewski JL, Homma S, and Berk PD. Cardiomyocyte triglyceride accumulation and reduced ventricular function in mice with obesity reflect increased long chain fatty acid uptake and de novo fatty acid synthesis. J Obes 2012: 205648, 2012.
91. Geloen A, Helin L, Geeraert B, Malaud E, Holvoet P, and Marguerie G. CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. PLoS One 7: e37633, 2012.
92. Ghafourifar P, Klein SD, Schucht O, Schenk U, Pruschy M, Rocha S, and Richter C. Ceramide induces cytochrome c release from isolated mitochondria. Importance of mitochondrial redox state. J Biol Chem 274: 6080-6084, 1999.
93. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92: 518-524, 2003.
94. Glancy B and Balaban RS. Role of mitochondrial Ca2+ in the regulation of cellular energetics. Biochemistry 51: 2959-2973, 2012.
95. Glatz JF, Luiken JJ, and Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev 90: 367-417, 2010.
96. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Van Arsdall M, Adrogue JV, Brown KK, and Taegtmeyer H. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 289: E328-E336, 2005.
97. Greenwalt DE, Scheck SH, and Rhinehart-Jones T. Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest 96: 1382-1388, 1995.
98. Greer JJ, Ware DP, and Lefer DJ. Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 290: H146-H153, 2006.
99. Guo X, Wu J, Du J, Ran J, and Xu J. Platelets of type 2 diabetic patients are characterized by high ATP content and low mitochondrial membrane potential. Platelets 20: 588-593, 2009.
100. Haemmerle G, Lass A, Zimmermann R, Gorkiewicz G, Meyer C, Rozman J, Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Hoefler G, and Zechner R. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312: 734-737, 2006.
101. Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, Radner FP, Preiss-Landl K, Kolbe T, Rulicke T, Pieske B, Trauner M, Lass A, Zimmermann R, Hoefler G, Cinti S, Kershaw EE, Schrauwen P, Madeo F, Mayer B, and Zechner R. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-alpha and PGC-1. Nat Med 17: 1076-1085, 2011.
102. Hall ME, Maready MW, Hall JE, and Stec DE. Rescue of cardiac leptin receptors in db/db mice prevents myocardial triglyceride accumulation. Am J Physiol Endocrinol Metab 307: E316-E325, 2014.
103. Hansford RG and Zorov D. Role of mitochondrial calcium transport in the control of substrate oxidation. Mol Cell Biochem 184: 359-369, 1998.
104. Hausenblas HA, Schoulda JA, and Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus - systematic review and meta-analysis. Mol Nutr Food Res 19: 201400173, 2014.
105. Haworth RA and Hunter DR. The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch Biochem Biophys 195: 460-467, 1979.
106. Hayashi K, Okumura K, Matsui H, Murase K, Kamiya H, Saburi Y, Numaguchi Y, Toki Y, and Hayakawa T. Involvement of 1,2-diacylglycerol in improvement of heart function by etomoxir in diabetic rats. Life Sci 68: 1515-1526, 2001.
107. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, and Gropler RJ. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47: 598-604, 2006.
108. Hickson-Bick DL, Buja LM, and McMillin JB. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 32: 511-519, 2000.
109. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, and Rhein S. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 113: 205-212, 2007.
110. Hoppins S. The regulation of mitochondrial dynamics. Curr Opin Cell Biol 29C: 46-52, 2014.
111. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, and Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55: 466-473, 2006.
112. Hunter DR and Haworth RA. The Ca2+-induced membrane transition in mitochondria. I. The protective mechanisms. Arch Biochem Biophys 195: 453-459, 1979.
113. Hunter DR and Haworth RA. The Ca2+-induced membrane transition in mitochondria. III. Transitional Ca2+ release. Arch Biochem Biophys 195: 468-477, 1979.
114. Huynh K, Kiriazis H, Du XJ, Love JE, Gray SP, Jandeleit-Dahm KA, McMullen JR, and Ritchie RH. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med 60: 307-317, 2013.
115. Huynh K, Kiriazis H, Du XJ, Love JE, Jandeleit-Dahm KA, Forbes JM, McMullen JR, and Ritchie RH. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 55: 1544-1553, 2012.
116. Il'yasova D, Wang F, D'Agostino RB, Jr., Hanley A, and Wagenknecht LE. Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose. Diabetologia 53: 866-874, 2010.
117. Jaconi M, Bony C, Richards SM, Terzic A, Arnaudeau S, Vassort G, and Puceat M. Inositol 1,4,5-trisphosphate directs Ca(2+) flow between mitochondria and the endoplasmic/sarcoplasmic reticulum: a role in regulating cardiac autonomic Ca(2+) spiking. Mol Biol Cell 11: 1845-1858, 2000.
118. Jawien J, Nastalek P, and Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 55: 503-517, 2004.
119. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, and Malloy CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 25: 469-472, 1995.
120. Jensen MD, Haymond MW, Rizza RA, Cryer PE, and Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83: 1168-1173, 1989.
121. Joffe II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, Morgan JP, and Douglas PS. Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 34: 2111-2119, 1999.
122. Joseph AM and Hood DA. Relationships between exercise, mitochondrial biogenesis and type 2 diabetes. Med Sport Sci 60: 48-61, 2014.
123. Joshi M, Kotha SR, Malireddy S, Selvaraju V, Satoskar AR, Palesty A, McFadden DW, Parinandi NL, and Maulik N. Conundrum of pathogenesis of diabetic cardiomyopathy: role of vascular endothelial dysfunction, reactive oxygen species, and mitochondria. Mol Cell Biochem 386: 233-249, 2014.
124. Jouaville LS, Pinton P, Bastianutto C, Rutter GA, and Rizzuto R. Regulation of mitochondrial ATP synthesis by calcium: evidence for a long-term metabolic priming. Proc Natl Acad Sci U S A 96: 13807-13812, 1999.
125. Kaludercic N, Carpi A, Nagayama T, Sivakumaran V, Zhu G, Lai EW, Bedja D, De Mario A, Chen K, Gabrielson KL, Lindsey ML, Pacak K, Takimoto E, Shih JC, Kass DA, Di Lisa F, and Paolocci N. Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 20: 267-280, 2014.
126. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, and Paolocci N. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res 106: 193-202, 2010.
127. Kanety H, Hemi R, Papa MZ, and Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 271: 9895-9897, 1996.
128. Kannel WB, Hjortland M, and Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34: 29-34, 1974.
129. Kantor PF, Lucien A, Kozak R, and Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86: 580-588, 2000.
130. Kelly DP and Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 18: 357-368, 2004.
131. Kienesberger PC, Pulinilkunnil T, Nagendran J, and Dyck JR. Myocardial triacylglycerol metabolism. J Mol Cell Cardiol 55: 101-110, 2013.
132. Kienesberger PC, Pulinilkunnil T, Nagendran J, Young ME, Bogner-Strauss JG, Hackl H, Khadour R, Heydari E, Haemmerle G, Zechner R, Kershaw EE, and Dyck JR. Early structural and metabolic cardiac remodelling in response to inducible adipose triglyceride lipase ablation. Cardiovasc Res 99: 442-451, 2013.
133. Kienesberger PC, Pulinilkunnil T, Sung MM, Nagendran J, Haemmerle G, Kershaw EE, Young ME, Light PE, Oudit GY, Zechner R, and Dyck JR. Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction. Mol Cell Biol 32: 740-750, 2012.
134. Kietadisorn R, Juni RP, and Moens AL. Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic possibilities. Am J Physiol Endocrinol Metab 302: E481-E495, 2012.
135. Knuuti J, Takala TO, Nagren K, Sipila H, Turpeinen AK, Uusitupa MI, and Nuutila P. Myocardial fatty acid oxidation in patients with impaired glucose tolerance. Diabetologia 44: 184-187, 2001.
136. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, and Dyck JR. CD36 expression contributes to age-induced cardiomyopathy in mice. Circulation 116: 2139-2147, 2007.
137. Koonen DP, Glatz JF, Bonen A, and Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 1736: 163-180, 2005.
138. Kooy A, de Jager J, Lehert P, Bets D, Wulffele MG, Donker AJ, and Stehouwer CD. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169: 616-625, 2009.
139. Korshunov SS, Skulachev VP, and Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 416: 15-18, 1997.
140. Kosiborod M, Arnold SV, Spertus JA, McGuire DK, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones PG, Olmsted A, Belardinelli L, and Chaitman BR. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects with Chronic Stable Angina). J Am Coll Cardiol 61: 2038-2045, 2013.
141. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, and Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7: 45-56, 2008.
142. Kranstuber AL, Del Rio C, Biesiadecki BJ, Hamlin RL, Ottobre J, Gyorke S, and Lacombe VA. Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling. Front Physiol 3: 292, 2012.
143. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, and Dyck JR. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation 109: 1550-1557, 2004.
144. Kumar S, Prasad S, and Sitasawad SL. Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats. PLoS One 8: e67009, 2013.
145. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, and Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122, 2006.
146. Lamant M, Smih F, Harmancey R, Philip-Couderc P, Pathak A, Roncalli J, Galinier M, Collet X, Massabuau P, Senard JM, and Rouet P. ApoO, a novel apolipoprotein, is an original glycoprotein up-regulated by diabetes in human heart. J Biol Chem 281: 36289-36302, 2006.
147. Lamb HJ, Beyerbacht HP, van der Laarse A, Stoel BC, Doornbos J, van der Wall EE, and de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99: 2261-2267, 1999.
148. Lashin OM, Szweda PA, Szweda LI, and Romani AM. Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. Free Radic Biol Med 40: 886-896, 2006.
149. Ledesma A, de Lacoba MG, and Rial E. The mitochondrial uncoupling proteins. Genome Biol 3: REVIEWS3015, 2002.
150. Lee GY, Kim NH, Zhao ZS, Cha BS, and Kim YS. Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochem J 378: 983-990, 2004.
151. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, and Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112: 3280-3288, 2005.
152. Leone TC, Weinheimer CJ, and Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPAR-alpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci U S A 96: 7473-7478, 1999.
153. Lexis CP, van der Horst IC, Lipsic E, Wieringa WG, de Boer RA, van den Heuvel AF, van der Werf HW, Schurer RA, Pundziute G, Tan ES, Nieuwland W, Willemsen HM, Dorhout B, Molmans BH, van der Horst-Schrivers AN, Wolffenbuttel BH, ter Horst GJ, van Rossum AC, Tijssen JG, Hillege HL, de Smet BJ, van der Harst P, and van Veldhuisen DJ. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 311: 1526-1535, 2014.
154. Li CJ, Zhang QM, Li MZ, Zhang JY, Yu P, and Yu DM. Attenuation of myocardial apoptosis by alpha-lipoic acid through suppression of mitochondrial oxidative stress to reduce diabetic cardiomyopathy. Chin Med J (Engl) 122: 2580-2586, 2009.
155. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, and Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 49: 1434-1446, 2006.
156. Li YJ, Wang PH, Chen C, Zou MH, and Wang DW. Improvement of mechanical heart function by trimetazidine in db/db mice. Acta Pharmacol Sin 31: 560-569, 2010.
157. Lin CH, Kurup S, Herrero P, Schechtman KB, Eagon JC, Klein S, Davila-Roman VG, Stein RI, Dorn GW, 2nd, Gropler RJ, Waggoner AD, and Peterson LR. Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss. Obesity (Silver Spring) 19: 1804-1812, 2011.
158. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, and Barletta A. From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr Metab Cardiovasc Dis 19: 146-152, 2009.
159. Liu J, Zhou J, An W, Lin Y, Yang Y, and Zang W. Apocynin attenuates pressure overload-induced cardiac hypertrophy in rats by reducing levels of reactive oxygen species. Can J Physiol Pharmacol 88: 745-752, 2010.
160. Liu K, Zhou R, Wang B, and Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 99: 1510-1519, 2014.
161. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, Schaffer JE, Yu YH, and Goldberg IJ. DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem 284: 36312-36323, 2009.
162. Lopaschuk GD, Barr R, Thomas PD, and Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 93: e33-e37, 2003.
163. Lopaschuk GD, McNeil GF, and McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol Cell Biochem 88: 175-179, 1989.
164. Lopaschuk GD, Tahiliani AG, Vadlamudi RV, Katz S, and McNeill JH. Cardiac sarcoplasmic reticulum function in insulin- or carnitine-treated diabetic rats. Am J Physiol 245: H969-H976, 1983.
165. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, and Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90: 207-258, 2010.
166. Lopaschuk GD, Wall SR, Olley PM, and Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 63: 1036-1043, 1988.
167. Luiken JJ, Arumugam Y, Bell RC, Calles-Escandon J, Tandon NN, Glatz JF, and Bonen A. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol Endocrinol Metab 283: E612-E621, 2002.
168. Luiken JJ, Arumugam Y, Dyck DJ, Bell RC, Pelsers MM, Turcotte LP, Tandon NN, Glatz JF, and Bonen A. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 276: 40567-40573, 2001.
169. Luiken JJ, Koonen DP, Willems J, Zorzano A, Becker C, Fischer Y, Tandon NN, Van Der Vusse GJ, Bonen A, and Glatz JF. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51: 3113-3119, 2002.
170. Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, and O'Rourke B. Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res 99: 172-182, 2006.
171. Marciniak C, Marechal X, Montaigne D, Neviere R, and Lancel S. Cardiac contractile function and mitochondrial respiration in diabetes-related mouse models. Cardiovasc Diabetol 13: 118, 2014.
172. Maritim AC, Sanders RA, and Watkins JB, 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17: 24-38, 2003.
173. Matsushima S, Kinugawa S, Ide T, Matsusaka H, Inoue N, Ohta Y, Yokota T, Sunagawa K, and Tsutsui H. Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Am J Physiol Heart Circ Physiol 291: H2237-H2245, 2006.
174. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, and Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53: 2366-2374, 2004.
175. McGarry JD and Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244: 1-14, 1997.
176. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, and Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116: 1170-1175, 2007.
177. Mendez-Del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, and Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 12: 497-501, 2014.
178. Meng D, Feng L, Chen XJ, Yang D, and Zhang JN. Trimetazidine improved Ca2+ handling in isoprenaline-mediated myocardial injury of rats. Exp Physiol 91: 591-601, 2006.
179. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, and Matsuo H. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101: 899-907, 2000.
180. Mohammadshahi M, Haidari F, and Soufi FG. Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress. Cardiol J 21: 39-46, 2014.
181. Montaigne D, Marechal X, Coisne A, Debry N, Modine T, Fayad G, Potelle C, El Arid JM, Mouton S, Sebti Y, Duez H, Preau S, Remy-Jouet I, Zerimech F, Koussa M, Richard V, Neviere R, Edme JL, Lefebvre P, and Staels B. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130: 554-564, 2014.
182. Morrow DA, Scirica BM, Chaitman BR, McGuire DK, Murphy SA, Karwatowska-Prokopczuk E, McCabe CH, and Braunwald E. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 119: 2032-2039, 2009.
183. Murray AJ, Panagia M, Hauton D, Gibbons GF, and Clarke K. Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 54: 3496-3502, 2005.
184. Nagendran J, Pulinilkunnil T, Kienesberger PC, Sung MM, Fung D, Febbraio M, and Dyck JR. Cardiomyocyte-specific ablation of CD36 improves post-ischemic functional recovery. J Mol Cell Cardiol 63: 180-188, 2013.
185. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, and Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98: 794-799, 1998.
186. Neely JR and Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 36: 413-459, 1974.
187. Netticadan T, Temsah RM, Kent A, Elimban V, and Dhalla NS. Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes 50: 2133-2138, 2001.
188. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000.
189. Normand-Lauziere F, Frisch F, Labbe SM, Bherer P, Gagnon R, Cunnane SC, and Carpentier AC. Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. PLoS One 5: e10956, 2010.
190. Oliveira PJ, Rolo AP, Seica R, Palmeira CM, Santos MS, and Moreno AJ. Decreased susceptibility of heart mitochondria from diabetic GK rats to mitochondrial permeability transition induced by calcium phosphate. Biosci Rep 21: 45-53, 2001.
191. Oliveira PJ, Rolo AP, Seica R, Sardao V, Monteiro P, Goncalves L, Providencia L, Palmeira CM, Santos MS, and Moreno AJ. Impact of diabetes on induction of the mitochondrial permeability transition. Rev Port Cardiol 21: 759-766, 2002.
192. Oliveira PJ, Seica R, Coxito PM, Rolo AP, Palmeira CM, Santos MS, and Moreno AJ. Enhanced permeability transition explains the reduced calcium uptake in cardiac mitochondria from streptozotocin-induced diabetic rats. FEBS Lett 554: 511-514, 2003.
193. Opie L. The Heart: Physiology and Metabolism. New York: Raven, 1991.
194. Opie L. Heart Physiology: From Cell to Circulation. Philadephia, PA: Lippincott Williams and Wilkins, 2004.
195. Ostrander DB, Sparagna GC, Amoscato AA, McMillin JB, and Dowhan W. Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis. J Biol Chem 276: 38061-38067, 2001.
196. Ouwens DM, Diamant M, Fodor M, Habets DD, Pelsers MM, El Hasnaoui M, Dang ZC, van den Brom CE, Vlasblom R, Rietdijk A, Boer C, Coort SL, Glatz JF, and Luiken JJ. Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterification. Diabetologia 50: 1938-1948, 2007.
197. Palumbo PJ. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc 76: 609-618, 2001.
198. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, and Goldberg IJ. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49: 2101-2112, 2008.
199. Penpargkul S, Fein F, Sonnenblick EH, and Scheuer J. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol 13: 303-309, 1981.
200. Penumathsa SV, Thirunavukkarasu M, Zhan L, Maulik G, Menon VP, Bagchi D, and Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med 12: 2350-2361, 2008.
201. Petersen KF, Dufour S, Befroy D, Garcia R, and Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350: 664-671, 2004.
202. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, and Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109: 2191-2196, 2004.
203. Philip-Couderc P, Smih F, Pelat M, Vidal C, Verwaerde P, Pathak A, Buys S, Galinier M, Senard JM, and Rouet P. Cardiac transcriptome analysis in obesity-related hypertension. Hypertension 41: 414-421, 2003.
204. Pierce GN and Dhalla NS. Heart mitochondrial function in chronic experimental diabetes in rats. Can J Cardiol 1: 48-54, 1985.
205. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, and Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481, 2008.
206. Polonsky KS. The past 200 years in diabetes. N Engl J Med 367: 1332-1340, 2012.
207. Poulsen MK, Henriksen JE, Dahl J, Johansen A, Gerke O, Vach W, Haghfelt T, Hoilund-Carlsen PF, Beck-Nielsen H, and Moller JE. Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease. Circ Cardiovasc Imaging 3: 24-31, 2010.
208. Preiss D, Lloyd SM, Ford I, McMurray JJ, Holman RR, Welsh P, Fisher M, Packard CJ, and Sattar N. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2: 116-124, 2014.
209. Pulinilkunnil T, Kienesberger PC, Nagendran J, Sharma N, Young ME, and Dyck JR. Cardiac-specific adipose triglyceride lipase overexpression protects from cardiac steatosis and dilated cardiomyopathy following diet-induced obesity. Int J Obes (Lond) 38: 205-215, 2014.
210. Pulinilkunnil T, Kienesberger PC, Nagendran J, Waller TJ, Young ME, Kershaw EE, Korbutt G, Haemmerle G, Zechner R, and Dyck JR. Myocardial adipose triglyceride lipase overexpression protects diabetic mice from the development of lipotoxic cardiomyopathy. Diabetes 62: 1464-1477, 2013.
211. Redfield MM, Jacobsen SJ, Burnett JC, Jr., Mahoney DW, Bailey KR, and Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194-202, 2003.
212. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, and Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 60: 884-899, 1977.
213. Ren J, Dominguez LJ, Sowers JR, and Davidoff AJ. Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes 45: 1822-1825, 1996.
214. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW, and Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54: 1524-1532, 2009.
215. Ritchie RH, Love JE, Huynh K, Bernardo BC, Henstridge DC, Kiriazis H, Tham YK, Sapra G, Qin C, Cemerlang N, Boey EJ, Jandeleit-Dahm K, Du XJ, and McMullen JR. Enhanced phosphoinositide 3-kinase(p110alpha) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 55: 3369-3381, 2012.
216. Robb-Gaspers LD, Burnett P, Rutter GA, Denton RM, Rizzuto R, and Thomas AP. Integrating cytosolic calcium signals into mitochondrial metabolic responses. EMBO J 17: 4987-5000, 1998.
217. Rolo AP and Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212: 167-178, 2006.
218. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, and Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: 595-602, 1972.
219. Rupp H, Elimban V, and Dhalla NS. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor. FASEB J 6: 2349-2353, 1992.
220. Rupp H, Wahl R, and Hansen M. Influence of diet and carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic reticulum. J Appl Physiol (1985) 72: 352-360, 1992.
221. Russell LK, Mansfield CM, Lehman JJ, Kovacs A, Courtois M, Saffitz JE, Medeiros DM, Valencik ML, McDonald JA, and Kelly DP. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 94: 525-533, 2004.
222. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson PW, and Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107: 448-454, 2003.
223. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, and Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107: 3040-3046, 2003.
224. Schmidt-Schweda S and Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 99: 27-35, 2000.
225. Schmitz FJ, Rosen P, and Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor etomoxir. Horm Metab Res 27: 515-522, 1995.
226. Scirica BM. Ranolazine in patients with coronary artery disease. Expert Opin Pharmacother 8: 2149-2157, 2007.
227. Selemidis S, Sobey CG, Wingler K, Schmidt HH, and Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120: 254-291, 2008.
228. Semeniuk LM, Kryski AJ, and Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 283: H976-H982, 2002.
229. Serpillon S, Floyd BC, Gupte RS, George S, Kozicky M, Neito V, Recchia F, Stanley W, Wolin MS, and Gupte SA. Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 297: H153-H162, 2009.
230. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, and Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18: 1692-1700, 2004.
231. Shaughnessy DT, McAllister K, Worth L, Haugen AC, Meyer JN, Domann FE, Van Houten B, Mostoslavsky R, Bultman SJ, Baccarelli AA, Begley TJ, Sobol R, Hirschey MD, Ideker T, Santos JH, Copeland WC, Tice RR, Balshaw DM, and Tyson FL. Mitochondria, energetics, epigenetics, and cellular responses to stress. Environ Health Perspect 122: 1271-1278, 2014.
232. Shen E, Li Y, Shan L, Zhu H, Feng Q, Arnold JM, and Peng T. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 58: 2386-2395, 2009.
233. Shen X, Zheng S, Metreveli NS, and Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55: 798-805, 2006.
234. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, Pinkett T, Ghali JK, and Wilson AC. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77: 1017-1020, 1996.
235. Silva JE. Physiological importance and control of non-shivering facultative thermogenesis. Front Biosci (Schol Ed) 3: 352-371, 2011.
236. Singh CK, Kumar A, Lavoie HA, Dipette DJ, and Singh US. Diabetic complications in pregnancy: is resveratrol a solution? Exp Biol Med 238: 482-490, 2013.
237. Sivitz WI and Yorek MA. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 12: 537-577, 2010.
238. Skulachev VP. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Q Rev Biophys 29: 169-202, 1996.
239. Sloan RC, Moukdar F, Frasier CR, Patel HD, Bostian PA, Lust RM, and Brown DA. Mitochondrial permeability transition in the diabetic heart: contributions of thiol redox state and mitochondrial calcium to augmented reperfusion injury. J Mol Cell Cardiol 52: 1009-1018, 2012.
240. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, and Goldberg IJ. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest 120: 3443-3454, 2010.
241. Soufi FG, Vardyani M, Sheervalilou R, Mohammadi M, and Somi MH. Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys 31: 431-438, 2012.
242. Stanley BA, Sivakumaran V, Shi S, McDonald I, Lloyd D, Watson WH, Aon MA, and Paolocci N. Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. J Biol Chem 286: 33669-33677, 2011.
243. Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC, Chandler MP, Cheng J, Dyck JR, and Lopaschuk GD. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol 289: H2304-H2309, 2005.
244. Su HC, Hung LM, and Cheng JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 290: 1339-1346, 2006.
245. Suarez J, Scott B, and Dillmann WH. Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol 295: R1439-R1445, 2008.
246. Sulaiman M, Matta MJ, Sunderesan NR, Gupta MP, Periasamy M, and Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 298: H833-H843, 2010.
247. Sung MM, Koonen DP, Soltys CL, Jacobs RL, Febbraio M, and Dyck JR. Increased CD36 expression in middle-aged mice contributes to obesity-related cardiac hypertrophy in the absence of cardiac dysfunction. J Mol Med (Berl) 89: 459-469, 2011.
248. Szabadkai G and Duchen MR. Mitochondria: the hub of cellular Ca2 + signaling. Physiology (Bethesda) 23: 84-94, 2008.
249. Szkudelski T. The insulin-suppressive effect of resveratrol - an in vitro and in vivo phenomenon. Life Sci 82: 430-435, 2008.
250. Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur J Pharmacol 552: 176-181, 2006.
251. Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am J Physiol Endocrinol Metab 293: E901-E907, 2007.
252. Szkudelski T and Szkudelska K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci 1215: 34-39, 2011.
253. Tanaka Y, Konno N, and Kako KJ. Mitochondrial dysfunction observed in situ in cardiomyocytes of rats in experimental diabetes. Cardiovasc Res 26: 409-414, 1992.
254. Tanno M, Kuno A, Horio Y, and Miura T. Emerging beneficial roles of sirtuins in heart failure. Basic Res Cardiol 107: 273, 2012.
255. Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K, and Horio Y. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 285: 8375-8382, 2010.
256. Thackeray JT, Beanlands RS, and Dasilva JN. Altered sympathetic nervous system signaling in the diabetic heart: emerging targets for molecular imaging. Am J Nucl Med Mol Imaging 2: 314-334, 2012.
257. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, and Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14: 612-622, 2011.
258. Timmis AD, Chaitman BR, and Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 27: 42-48, 2006.
259. Tocchetti CG, Caceres V, Stanley BA, Xie C, Shi S, Watson WH, O'Rourke B, Spadari-Bratfisch RC, Cortassa S, Akar FG, Paolocci N, and Aon MA. GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. Diabetes 61: 3094-3105, 2012.
260. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, and Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51: 1166-1171, 2002.
261. Turkieh A, Caubere C, Barutaut M, Desmoulin F, Harmancey R, Galinier M, Berry M, Dambrin C, Polidori C, Casteilla L, Koukoui F, Rouet P, and Smih F. Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart. J Clin Invest 124: 2277-2286, 2014.
262. Turpeinen AK, Takala TO, Nuutila P, Axelin T, Luotolahti M, Haaparanta M, Bergman J, Hamalainen H, Iida H, Maki M, Uusitupa MI, and Knuuti J. Impaired free fatty acid uptake in skeletal muscle but not in myocardium in patients with impaired glucose tolerance: studies with PET and 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid. Diabetes 48: 1245-1250, 1999.
263. Ueno M, Suzuki J, Zenimaru Y, Takahashi S, Koizumi T, Noriki S, Yamaguchi O, Otsu K, Shen WJ, Kraemer FB, and Miyamori I. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am J Physiol Endocrinol Metab 294: E1109-E1118, 2008.
264. Ussher JR, Fillmore N, Keung W, Mori J, Beker DL, Wagg CS, Jaswal JS, and Lopaschuk GD. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice. Can J Cardiol 30: 940-944, 2014.
265. Ussher JR, Folmes CD, Keung W, Fillmore N, Jaswal JS, Cadete VJ, Beker DL, Lam VH, Zhang L, and Lopaschuk GD. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS One 7: e37703, 2012.
266. Ussher JR, Koves TR, Jaswal JS, Zhang L, Ilkayeva O, Dyck JR, Muoio DM, and Lopaschuk GD. Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes 58: 1766-1775, 2009.
267. van de Weijer T, Schrauwen-Hinderling VB, and Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res 92: 10-18, 2011.
268. van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JW, and Diamant M. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 119: 2069-2077, 2009.
269. Vetter R and Rupp H. CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins. Am J Physiol 267: H2091-H2099, 1994.
270. Vinereanu D, Nicolaides E, Tweddel AC, Madler CF, Holst B, Boden LE, Cinteza M, Rees AE, and Fraser AG. Subclinical left ventricular dysfunction in asymptomatic patients with type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci (Lond) 105: 591-599, 2003.
271. Wall SR and Lopaschuk GD. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim Biophys Acta 1006: 97-103, 1989.
272. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256: 628-632, 1992.
273. Wang P, Lloyd SG, Zeng H, Bonen A, and Chatham JC. Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 288: H2102-H2110, 2005.
274. Wichi R, Malfitano C, Rosa K, De Souza SB, Salemi V, Mostarda C, De Angelis K, and Irigoyen MC. Non-invasive and invasive evaluation of cardiac dysfunction in experimental diabetes in rodents. Cardiovasc Diabetol 6: 14, 2007.
275. Widlansky ME, Wang J, Shenouda SM, Hagen TM, Smith AR, Kizhakekuttu TJ, Kluge MA, Weihrauch D, Gutterman DD, and Vita JA. Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes. Transl Res 156: 15-25, 2010.
276. Williamson CL, Dabkowski ER, Baseler WA, Croston TL, Alway SE, and Hollander JM. Enhanced apoptotic propensity in diabetic cardiac mitochondria: influence of subcellular spatial location. Am J Physiol Heart Circ Physiol 298: H633-H642, 2010.
277. Wojtczak L and Schonfeld P. Effect of fatty acids on energy coupling processes in mitochondria. Biochim Biophys Acta 1183: 41-57, 1993.
278. Wold LE, Ceylan-Isik AF, and Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 26: 908-917, 2005.
279. Xu Q, Dalic A, Fang L, Kiriazis H, Ritchie RH, Sim K, Gao XM, Drummond G, Sarwar M, Zhang YY, Dart AM, and Du XJ. Myocardial oxidative stress contributes to transgenic beta(2)-adrenoceptor activation-induced cardiomyopathy and heart failure. Br J Pharmacol 162: 1012-1028, 2011.
280. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, and Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426, 2003.
281. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, and Kelly DP. CD36 deficiency rescues lipotoxic cardiomyopathy. Circ Res 100: 1208-1217, 2007.
282. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, and Epstein PN. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53: 1336-1343, 2004.
283. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH, and de Boer RA. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol 301: H459-H468, 2011.
284. Yu CM, Lin H, Yang H, Kong SL, Zhang Q, and Lee SW. Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 105: 1195-1201, 2002.
285. Yu T, Sheu SS, Robotham JL, and Yoon Y. Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species. Cardiovasc Res 79: 341-351, 2008.
286. Yue P, Arai T, Terashima M, Sheikh AY, Cao F, Charo D, Hoyt G, Robbins RC, Ashley EA, Wu J, Yang PC, and Tsao PS. Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. Am J Physiol Heart Circ Physiol 292: H2106-H2118, 2007.
287. Zabalgoitia M, Ismaeil MF, Anderson L, and Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 87: 320-323, 2001.
288. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, and Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 12: 114-120, 1988.
289. Zhang H, Morgan B, Potter BJ, Ma L, Dellsperger KC, Ungvari Z, and Zhang C. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol 299: H985-H994, 2010.
290. Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, and Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 89: 148-156, 2011.
291. Zhang P, Hou M, Li Y, Xu X, Barsoum M, Chen Y, and Bache RJ. NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart. Am J Physiol Heart Circ Physiol 296: H840-H846, 2009.
292. Zhao P, Zhang J, Yin XG, Maharaj P, Narraindoo S, Cui LQ, and Tang YS. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci 92: 633-638, 2013.
293. Zhao W, Zhao T, Chen Y, Ahokas RA, and Sun Y. Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 317: 43-50, 2008.
294. Zhong Y, Ahmed S, Grupp IL, and Matlib MA. Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol Heart Circ Physiol 281: H1137-H1147, 2001.
295. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, and Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97: 1784-1789, 2000.
296. Zorov DB, Filburn CR, Klotz LO, Zweier JL, and Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med 192: 1001-1014, 2000.
297. Zorov DB, Juhaszova M, and Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94: 909-950, 2014.